Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities by Charlotte Lemech, Hendrik-Tobias Arkenau

Get full text

Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities by Charlotte Lemech, Hendrik-Tobias Arkenau

Get full text

Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence by Mark Voskoboynik, Hendrik-Tobias Arkenau

Get full text

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence by Charlotte Lemech, Jeffrey Infante, Hendrik-Tobias Arkenau

Get full text

Research biopsies in the context of early phase oncology studies: clinical and ethical considerations by Matilde Saggese, Divyanshu Dua, Emily Simmons, Charlotte Lemech, Hendrik-Tobias Arkenau

Signal pathways and precision therapy of small-cell lung cancer by Min Yuan, Yu Zhao, Hendrik-Tobias Arkenau, Tongnei Lao, Li Chu, Qing Xu

Get full text

Mammographic Breast Density and Urbanization: Interactions with BMI, Environmental, Lifestyle, and Other Patient Factors by Nick Perry, Sue Moss, Steve Dixon, Sue Milner, Kefah Mokbel, Charlotte Lemech, Hendrik-Tobias Arkenau, Stephen Duffy, Katja Pinker

Get full text

Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience by Hendrik-Tobias Arkenau, Geoff Chong, David Cunningham, David Watkins, Bhawna Sirohi, Ian Chau, Andrew Wotherspoon, Andy Norman, Alan Horwich, Estella Matutes

Get full text

Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study by Arunkumar Krishnan, Carolin V. Schneider, Hendrik-Tobias Arkenau, Ezequiel Matias Mauro, Alejandro Forner, W. Scott Butsch, Declan Walsh, Saleh A. Alqahtani

Get full text

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy by Hendrik-Tobias Arkenau, Jean-Yves Douillard, Nicolas Penel, Teresa Amaral, Ahmad Awada, Emiliano Calvo, Viktor Gruenwald, Jose Luis Perez-Gracia, Ruth Vera, Martijn P Lolkema, Gyorgy Bodoky, Massimo Di Nicola, Miguel F Sanmamed

Get full text

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors by Agostina Stradella, Melissa Johnson, Sanjay Goel, Haeseong Park, Nehal Lakhani, Hendrik‐Tobias Arkenau, Matthew D. Galsky, Emiliano Calvo, Vicente Baz, Victor Moreno, Omar Saavedra, Stephen J. Luen, Song Mu, Qiting Wan, Victoria Chang, Wa Zhang, Minal Barve

Get full text

525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors... by Hendrik-Tobias Arkenau, Emiliano Calvo, Alain Mita, Young Kwang Chae, Devalingam Mahalingam, Ugur Sahin, Elena Garralda, Oezlem Tuereci, Vladimir Galvao, Stefan Symeonides, Maria Miguel, Hariz Hassan, Annette Baumhauer, Timo Völker, Marie-Cristine Kühnle, Roman Rösemann, Stefan Strobl

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer by Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer

Get full text

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study by Hendrik-Tobias Arkenau, Marta Gil-Martin, Fiona Thistlethwaite, Aung Naing, Karen A. Autio, Patrick A. Ott, Johanna Bendell, Patricia LoRusso, Valentina Boni, Alexander Spira, Javier Garcia-Corbacho, Mark Stroh, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Manreet Randhawa, Greg Durm, Alison L. Hannah

Get full text

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVEL... by Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R. Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith, Arnold B. Gelb, Huiling Xiong, Janet Hong, Vikram Chand, Howard Safran

Get full text

Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study by Do-Youn Oh, Maria Alsina Maqueda, David I. Quinn, Peter J. O’Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K. Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P. Dean, Hendrik-Tobias Arkenau

Get full text